Terrence Kearney - Vertex Pharmaceuticals Independent Director

VRTX -- USA Stock  

USD 176.14  1.62  0.93%

  Director
Mr. Terrence C. Kearney is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Kearney served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication delivery company, from April 2006 to January 2011. From April 2004 to April 2006, he served as Hospiras Senior Vice President, Finance, and Chief Financial Officer, and he served as Acting Chief Financial Officer through August 2006. Mr. Kearney served as Vice President and Treasurer of Abbott Laboratories from 2001 to April 2004. From 1996 to 2001, Mr. Kearney was Divisional Vice President and Controller for Abbotts International Division. Mr. Kearney serves as a member of the Board of Directors at Acceleron Pharma Inc., a biopharmaceutical company. He served as a member of the Board of Directors of Innovia, a royalty management company, from October 2014 through April 2016, and as member of the Board of Directors of AveXis, Inc., a gene therapy company, from January 2016 until its acquisition in May 2018
Age: 63  Director Since 2011  MBA    
617-341-6100  http://www.vrtx.com
Kearney was a member of the Board of Directors of Levo Therapeutics, Inc., a biotechnology company focused on developing treatments for PraderWilli Syndrome, since 2018. He received his B.S. in biology from the University of Illinois and his M.B.A. from the University of Denver.

Terrence Kearney Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Gregory NordenZoetis
2013
Frank DAmelioZoetis
2016
Jeffrey KindlerPerrigo Company plc
2017
Fei WangOrigin Agritech Limited
2019
Prasad MenonDr Reddys Laboratories Ltd
2019
Gary CohenPerrigo Company plc
2009
Gary KunklePerrigo Company plc
2009
Christine PoonRegeneron Pharmaceuticals
2010
James KangOrigin Agritech Limited
2010
Ashok GangulyDr Reddys Laboratories Ltd
2009
Laurie BrlasPerrigo Company plc
2016
Willie ReedZoetis
2014
Louise ParentZoetis
2013
Sridar IyengarDr Reddys Laboratories Ltd
2011
Shlomo YanaiPerrigo Company plc
N/A
Jeffrey SmithPerrigo Company plc
2017
Michael BrownRegeneron Pharmaceuticals
1991
Geoffrey ParkerPerrigo Company plc
2016
Adriana KaraboutisPerrigo Company plc
2017
Jacqualyn FousePerrigo Company plc
2012
Rolf ClassonPerrigo Company plc
2017

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
a day ago
Traded for 188.14
Purchased a lot of shares of
a day ago
Traded for 150.35
Purchased few shares of
a day ago
Traded for 175.29
Also please take a look at World Market Map. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.
Search macroaxis.com